Targeted spatial proteomic analysis of CD8
cytotoxic T lymphocytes (CTL)
head and neck (H&N) cancer
immune check point
myeloid cell
spatial proteomics
tonsillar cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
05
07
2023
accepted:
03
11
2023
medline:
4
12
2023
pubmed:
4
12
2023
entrez:
4
12
2023
Statut:
epublish
Résumé
Tonsillar cancer is caused by high-risk human papillomavirus (HPV), tobacco smoking, and alcohol abuse. Aspects of the patient's immune response to this disease have arisen as prognostic factors and treatment targets, reflecting differences in the type and protein expression profile of immune cells. Because tonsillar cancers are heterogenous lesions such data need to be spatially resolved. In this study, we aim to explore inter-patient and intra-tumoral sources of variation in tonsillar cancer using immunofluorescence and targeted spatial proteomics to interrogate a cohort of 105 patients. Furthermore, we assess prognostic factors and elucidate molecular targets. We have used CD8, CD11c, and Pan-cytokeratin (PanCK) to quantify and locate immune cells driving antigen-specific cellular immunity. Guided by immunofluorescence information, we selected 355 CD8 Quantitative analysis of immunofluorescence in combination with clinical data revealed that the abundance of total CD8 Our findings highlight the relevance of analyzing aspects of tumor micro-architecture in the search of prognostic markers and molecular targets for tonsillar cancer. The abundance of intra-tumoral CD8
Sections du résumé
Background
UNASSIGNED
Tonsillar cancer is caused by high-risk human papillomavirus (HPV), tobacco smoking, and alcohol abuse. Aspects of the patient's immune response to this disease have arisen as prognostic factors and treatment targets, reflecting differences in the type and protein expression profile of immune cells. Because tonsillar cancers are heterogenous lesions such data need to be spatially resolved.
Methods
UNASSIGNED
In this study, we aim to explore inter-patient and intra-tumoral sources of variation in tonsillar cancer using immunofluorescence and targeted spatial proteomics to interrogate a cohort of 105 patients. Furthermore, we assess prognostic factors and elucidate molecular targets. We have used CD8, CD11c, and Pan-cytokeratin (PanCK) to quantify and locate immune cells driving antigen-specific cellular immunity. Guided by immunofluorescence information, we selected 355 CD8
Results
UNASSIGNED
Quantitative analysis of immunofluorescence in combination with clinical data revealed that the abundance of total CD8
Conclusion
UNASSIGNED
Our findings highlight the relevance of analyzing aspects of tumor micro-architecture in the search of prognostic markers and molecular targets for tonsillar cancer. The abundance of intra-tumoral CD8
Identifiants
pubmed: 38044986
doi: 10.3389/fonc.2023.1253418
pmc: PMC10691541
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1253418Informations de copyright
Copyright © 2023 Altunbulakli, Jimenez, Askmyr, Sobti, Swoboda, Greiff and Lindstedt.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Oral Oncol. 2020 Feb;101:104516
pubmed: 31838340
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
Cancer Res. 2012 Jul 1;72(13):3163-74
pubmed: 22570253
J Exp Med. 2020 Oct 5;217(10):
pubmed: 32716518
N Engl J Med. 2010 Jul 1;363(1):24-35
pubmed: 20530316
Clin Cancer Res. 2018 Feb 1;24(3):634-647
pubmed: 29018052
Front Immunol. 2021 Jun 10;12:702726
pubmed: 34177968
Front Immunol. 2021 Jul 19;12:701006
pubmed: 34349762
Int J Cancer. 2013 Jan 1;132(1):72-81
pubmed: 22592660
Lancet Oncol. 2016 Apr;17(4):440-451
pubmed: 26936027
Front Immunol. 2021 Mar 12;12:635615
pubmed: 33777025
J Exp Clin Cancer Res. 2022 Sep 20;41(1):279
pubmed: 36123711
Eur J Cancer. 2013 Jul;49(11):2522-30
pubmed: 23571147
PLoS One. 2012;7(6):e38711
pubmed: 22701698
Front Oncol. 2015 Jun 08;5:117
pubmed: 26106583
J Clin Pathol. 2019 Aug;72(8):542-549
pubmed: 31113825
Sci Rep. 2017 Dec 4;7(1):16878
pubmed: 29203879
PLoS One. 2011 Apr 29;6(4):e19499
pubmed: 21559358
Head Neck. 2019 Feb;41(2):463-478
pubmed: 30549362
Front Oncol. 2021 Jan 19;10:607349
pubmed: 33542903
Br J Cancer. 2015 Sep 15;113(6):886-93
pubmed: 26313665
Ann Surg Oncol. 2010 Jun;17(6):1471-4
pubmed: 20180029
J Immunol. 2016 May 15;196(10):4064-74
pubmed: 27076679
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Front Immunol. 2023 Apr 03;14:1135489
pubmed: 37153589
Cancers (Basel). 2021 Oct 25;13(21):
pubmed: 34771506